相关临床试验
45
13 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
11.1%
已完成
19
42.2%
尚未招募
8
17.8%
招募中
9
20.0%
终止
3
6.7%
撤回
1
2.2%
暂无批准数据
- A collaborative study from RMIT, MIT, and Harvard Medical School identifies key formulation conditions that protect mRNA-carrying nanoparticles during drying and rehydration in microneedle patches. - The research, published in Advanced Functional Materials, explains why some dry patch formulations outperform others, providing practical guidance for future vaccine patch design. - Eliminating cold-chain requirements could address a critical barrier to vaccine access; in 2024, 14.3 million children globally received no vaccines at all, per WHO and UNICEF. - The findings build on prior MIT research showing patches can be printed and stored at room temperature, with next steps focused on optimizing formulations and testing immune responses.
- The Aikenhead Centre for Medical Discovery (ACMD), Australia's first hospital-based biomedical engineering research centre, has opened at St Vincent's Hospital in Fitzroy, Melbourne. - The AU$206 million facility brings together clinicians, scientists, and engineers to fast-track medical discoveries into patient benefits using AI, biotechnology, and regenerative medicine. - The centre can accommodate up to 900 researchers, train 300 new doctors annually, and features 3D printing labs, a kinetics lab, engineering workshops, and robotics. - Research will target chronic conditions including epilepsy, cancer, and osteoarthritis, with the goal of translating laboratory discoveries to the bedside faster and more reliably.
- Researchers at RMIT University have developed nanodots made from molybdenum oxide that selectively kill cancer cells while largely sparing healthy tissue. - Laboratory tests demonstrated the nanodots destroyed three times more cervical cancer cells than healthy cells within 24 hours without requiring light activation. - The particles work by releasing reactive oxygen molecules that trigger programmed cell death in cancer cells, which are already under higher stress than healthy cells. - The research represents an international collaboration between RMIT University, The Florey Institute, and several Chinese institutions, though testing remains limited to laboratory-grown cells.
- Australian researchers at RMIT University have developed experimental eyedrops using nano-cubosome technology to deliver lutein directly to the retina, potentially replacing painful eye injections for treating age-related macular degeneration and diabetic retinopathy. - The innovative delivery system uses cubosomes as tiny shields to protect lutein and release it in a controlled manner, successfully reaching retinal tissue in mouse studies and remaining stable at room temperature for months. - In laboratory tests, the lutein-loaded eyedrops reduced toxic compounds VEGF-A and IL-6 in retinal cells by activating the Nrf2/HO-1 antioxidant pathway, demonstrating potential therapeutic benefits. - While promising, the research remains in early stages with testing conducted only on healthy mice and cell cultures, requiring further animal studies and eventual human trials before clinical application.
- The Atmo Gas Capsule, originally invented at RMIT University, has received FDA 510(k) clearance for diagnosing gastrointestinal motility disorders including gastroparesis and slow transit constipation. - The regulatory approval was based on a pivotal clinical study involving more than 200 subjects across 12 trial sites in the US and Australia, demonstrating the device's safety and efficacy. - The ingestible capsule measures gases as it travels through the digestive system and wirelessly transmits data to provide clinicians with comprehensive diagnostic information. - Atmo Biosciences licensed the technology from RMIT in 2018 and will launch the market-ready device in July 2025, addressing an unmet clinical need affecting millions worldwide.
